CMV reactivation differentially affects CD56, NKG2C, and NKG2A NK cell expression among patients receiving TCD, T-replete, and DUCB HCT. Data gathered at late time points after different allograft infusions are shown. (A) CD56^bright (top) and CD56^dim (bottom) population frequencies within CD56⁺ NK cells in patients stratified based on the CMV reactivation status. (B) CD56^dim (left), CD56^bright (middle), and CD56^– (right) population frequencies within total NK cells in patients stratified according to CMV reactivation status. (C) NKG2A⁺ frequencies within CD56^bright (left), CD56^dim (middle), and CD56^– (right) NK cell subpopulations in patients, stratified based on the CMV reactivation status. (D) NKG2C⁺ frequencies within CD56^bright (left), CD56^dim (middle), and CD56^neg (right) NK cell subpopulations in patients, stratified based on the CMV reactivation status. (E) NKG2C⁺ frequencies in total NK cells including CD56^bright, CD56^dim, and CD56^– NK cells, from patients experiencing CMV reactivation. A threshold of 10%, separating individuals with or without expansion, was determined based on patients without CMV reactivation. Unpaired t tests were used for statistical analysis, with ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P ≤ .0001.